Shares of Replimune Group increased by 107% following a positive vote from a Food and Drug Administration (FDA) panel, which favored the company's experimental treatment for skin cancer with a 10-3 vote. This significant endorsement has created a surge in stock value, highlighting the potential impact of FDA decisions on biotech companies.

This copy is for your personal, non-commercial use only. Distribution and use of this material are governed by our Subscriber Agreement and by copyright law. For non-personal use or to order multiple copies, please contact Dow Jones Reprints at 1-800-843-0008 or visit www.djreprints.com.

This Biotech Stock Soars 107% After Key FDA Panel Vote on Skin Cancer Treatment

By Kit Norton

Resize

Reprints

In this article

REPL

A FDA panel on Thursday voted 10-3 in favor of a Replimune study of its experimental skin cancer treatment. (Dreamstime)

Shares ofReplimune Groupsurged Friday after a Food and Drug Administration panel voted in favor of the biotechnology company’sexperimental skin cancer treatment.

Barron’s Investor Circle

Chart of the Day: MercadoLibre Is Setting Up for a Breakout \ \ 0·18 hours ago\ \ Palo Alto Networks Rides the Cybersecurity Wave \ \ 0·18 hours ago\ \ Jones Lang LaSalle: Quantitative Stock of the Week \ \ 0·21 hours ago\ \ Video: The Stocks to Buy After Earnings, From Big Tech to Small-Caps \ \ 0·Jul 30, 2026\ \

Subscribe Learn More

Read Original at Barron's →